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a  b  s  t  r  a  c  t
Many  industrial  chemicals  and  their respective  by-products  need  to be  comprehensively
evaluated  for  toxicity  using  reliable  and  efficient  assays.  In terms  of teratogenicity  evalua-
tions,  the  murine-based  embryonic  stem  cell  test  (EST)  offers  a  promising  solution  to  screen
for  multiple  tissue  endpoints.  However,  use  of  a mouse  model  in the  EST  can  yield  only
a  limited  understanding  of human  development,  anatomy,  and  physiology.  Non-human
primate  or  human  in  vitro models  have  been  suggested  to be a pharmacologically  and
pathophysiologically  desirable  alternative  to  murine  in  vitro  models.  Here,  we  compara-
tively  evaluated  the  sensitivity  of embryonic  stem  cells (ESCs)  of  a non-human  primate  to
skeletal  teratogens  with mouse  ESCs  hypothesizing  that inclusion  of  non-human  primate
cells in in  vitro  tests  would  increase  the reliability  of  safety  predictions  for  humans.
First,  osteogenic  capacity  was  compared  between  ESCs  from  the  mouse  and a  New  World
monkey,  the  common  marmoset.  Then,  cells  were  treated  with  compounds  that  have  been
previously  reported  to  induce  bone  teratogenicity.  Calcification  and  MTT assays  evaluated
effects  on  osteogenesis  and  cell viability,  respectively.  Our  data indicated  that  marmoset
ESCs  responded  differently  than  mouse  ESCs  in such  embryotoxicity  screens  with  no  obvi-
ous  dependency  on chemical  or compound  classes  and  thus  suggest  that  embryotoxicity
screening  results  could  be affected  by  species-driven  response  variation.  In  addition,  ESCs
derived from  rhesus  monkey,  an  Old  World  monkey,  and  phylogenetically  closer  to  humans
than the marmoset,  were  observed  to respond  differently  to test compounds  than  marmoset
ESCs. Together  these  results  indicate  that there  are  significant  differences  in  the responses
of  non-human  primate  and  mouse  ESC  to  embryotoxic  agents.
©  2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
the  CC  BY  license  (http://creativecommons.org/licenses/by/4.0/).∗ Corresponding author at: Department of Cell Biology & Neuroscience,
113 Biological Sciences Building, University of California Riverside, River-
ide, CA 92521, USA. Tel.: +1 951 827 3818.
E-mail address: nicole.zurnieden@ucr.edu (N.I. zur Nieden).
http://dx.doi.org/10.1016/j.toxrep.2014.11.016
214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an op
icenses/by/4.0/).1. IntroductionIn the United States, one in 28 babies carries congenital
anomalies [1]. Although 50% of the causes for such birth
defects are unknown, some may  be traced back to invol-
untary environmental chemical exposure. There are more
en access article under the CC BY license (http://creativecommons.org/
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than 80,000 cataloged chemicals in the United States that
may  be released into the environment and most of them
are inappropriately tested for safety. This lack of infor-
mation is particularly concerning for sensitive populations
such as pregnant women and children as adequate safety
guidelines cannot always be confidently recommended.
Furthermore, given that the developing fetus is especially
sensitive to maternal environmental conditions and also
that exposure during key points of development can lead to
unique effects lasting through multiple generations [2], the
potential embryotoxicity and teratogenicity of industrial
compounds is of particular concern.
With appropriate data, acceptable exposure levels and
actual safety of such products can be established for
individuals that are most vulnerable to chemical expo-
sure. Therefore, toxicology programs have been designed
to identify toxicities that may  potentially be encoun-
tered in human embryos. Under the worldwide trend
for revision of chemical legislation, it will be necessary
to test a large number of chemicals in a short time,
which can only be achieved with predictive in vitro
assays.
A step in the direction of animal sacrifice free embryo-
toxicity screen was taken when the classic embryonic stem
cell test (EST) was first described [3,4]. This assay relies
on embryonic stem cells (ESCs) from the mouse and com-
pares two important aspects of prenatal toxicity. First, the
EST has revealed the differences in sensitivity of mouse
embryonic stem cells (ESCs) to chemical entities compared
to adult fibroblasts. Second, the test determines the ability
of a chemical to inhibit the differentiation of the ESCs into
a differentiated cell type of interest [5,6].
Among the many birth defects, the ones that affect mus-
culoskeletal tissues account for 5% of all infant deaths.
Thus, skeletal toxicity has become a high priority screening
phenotype and is currently integrated into the animal
screens that assess general prenatal developmental tox-
icity (TG414, OECD) [7–9]. Assessing the inhibition of
osteogenic differentiation of the ESCs, the EST may  also be
exploited to serve as predictor for developmental osteotox-
icity [6,10–14].
Despite the routine use of rodent models in research,
the mouse model as used in the EST can only yield a limited
understanding of human development, anatomy and phys-
iology. Accordingly, human in vitro models are desirable
from a pharmacological and pathophysiological stand-
point. Indeed, ESCs from humans were established around
the turn of the century [15]. However, due to ethical con-
siderations, the legality of their use varies widely between
countries. A solution comes with human induced pluripo-
tent stem cells (hiPSCs), which are artificially created from
somatic cells, and are therefore not ethically challenged,
but it is yet unclear how their quality or differentiation
potential measures up to bona fide hESCs. Therefore, to
provide a legal and ethical alternative to countries, which
have banned hESC research, we test here whether the
sensitivity of non-human primate ESCs to a small set of
classical and skeletal embryotoxic agents is similar to that
of mouse ESCs in order to evaluate whether the inclusion of
non-human primate cells into the EST would increase the
reliability of safety predictions for human use.orts 2 (2015) 165–174
2. Materials and methods
2.1. Murine ESC maintenance
Murine D3 embryonic stem cells (American Type Cul-
ture Collection, Rockville, MD,  USA) were expanded in high
glucose DMEM containing l-glutamine (Corning). Media
additionally contained 15% batch-tested fetal bovine serum
(FBS), 1% non-essential amino acids (NEAA), 50 U/ml peni-
cillin, 50 g/ml streptomycin, 0.1 mM 2-mercaptoethanol
(all Invitrogen) and 1000 U LIF/ml (Millipore). Cells were
routinely passaged every 2–3 days with 0.25% Trypsin-
EDTA (Life Technologies).
2.2. Maintenance culture of non-human primate ESCs
Embryonic stem cells from the common marmoset
(cjes001) were cultured in feeder-free conditions as
described [16]. Rhesus ESCs (R366.4, WiCell Research Insti-
tute) were cultured on mouse embryonic fibroblast feeder
layers as previously described [17,18].
2.3. Osteogenic differentiation of ESCs
Murine ESCs were induced to differentiate via aggre-
gation into embryoid bodies via hanging drops at 750
cells/drop, in the presence of control differentiation
medium (CDM, mouse ESC maintenance medium without
LIF [19]. Differentiating cells were replated on day 5 as a sin-
gle cell suspension at a concentration of 50,000 cells/cm2
[20]. Differentiation of marmoset and rhesus ESCs was initi-
ated from intact ESC colonies in non-adherent conditions as
described [16,17]. In brief, undifferentiated colonies were
trypsinized with TrypLE (Invitrogen) into clusters of 20–30
cells. Approximately 100 such clusters were seeded in CDM
to one bacteriological grade dish (100 mm diameter). Fol-
lowing 5 days of incubation, cell clusters were transferred
onto cell culture plates coated with 0.1% gelatin at an
approximate density of 10 cell clusters/cm2. On day 5 of
differentiation, cells from all species received osteogenic
differentiation medium containing the induction factors -
glycerophosphate (10 mM),  ascorbic acid (25 g/ml), and
1,25-(OH)2 vitamin D3 (5 × 10−8 M)  in CDM.
2.4. Test compounds
5-fluorouracil, all-trans retinoic acid, penicillin G (all
Sigma) were selected as control test compounds as the
teratogenic potential of each has been well established
by previous in vivo and in vitro investigations [21]. Stock
solutions were made in DMSO and diluted to test concen-
trations in respective cell culture media. Lithium chloride
was  obtained from Fluka and aluminum chloride was
obtained from Sigma. Sodium chloride (Fisher Scientific),
lithium acetate (Aldrich), sodium acetate (Sigma), and alu-
minum hydroxide (Sigma) were included as controls for
lithium and aluminum activity. Untreated control cul-
tures containing appropriate vehicle were also included.
Osteogenic differentiation was considered valid if the
control solvent yielded osteoblast differentiation levels
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omparable to that of untreated vitamin D3 induced
steogenic cultures.
.5. Cytotoxicity assay
Cellular viability was evaluated with an MTT  assay fol-
owing 14 days of osteogenic induction as described [22].
n brief, 0.5 mg/ml  MTT  solution was added to the cul-
ures and cells were incubated at 37 ◦C for 2 h. Reagent
as then aspirated and cells were gently rocked in pre-
armed MTT  desorb solution (0.7% SDS in 2-propanol) for
5 min. Absorbance of dissolved blue formazan product
as measured spectrophotometrically at 570 nm with a
30 nm reference wavelength. Mitochondrial activity was
ormalized to solvent only controls and resulting percent-
ges were graphed along the tested concentration range
o construct a concentration–response curve. The half-
aximal inhibitory effect (IC50) for each compound was
ubsequently established via linear interpolation of the
urve.
.6. Determination of Ca2+ content
.6.1. Alizarin Red S staining
Attached cells were washed with 1X PBS and fixed with
% paraformaldehyde in 1× PBS and incubated at 4 ◦C for
 h. Residual fixative was  quenched via incubation with
00 mM glycine for 15 min  at room temperature. Samples
ere then washed three times in 1× PBS and once in dH2O.
ixed cells were then subjected to a 0.5% Alizarin Red S
taining solution for 5 min. Following three washes with
H2O, subsequent washes were performed with ascending
thanol concentrations (i.e. 70%, 80%, 90%, and 100%). Cul-
ures were kept in 100% ethanol for acquisition of images.
.6.2. Quantification of calcium deposition
Cells were washed twice in 1× phosphate buffered
aline (PBS) and lysed in a modified RIPA buffer (1% NP-
0, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate
n 1× PBS, pH 7.4). Each plate was incubated for 1 h at
◦C with shaking to ensure complete cell lysis. Ca2+ con-
entration was measured against a set of standards using
n Arsenazo III based spectrophotometric assay (Genzyme
iagnostics) at 650 nm as described [23]. The protein con-
entration in each sample was then measured against a
et of standards using a Lowry spectrophotometric assay
Bio-Rad Laboratories) at 750 nm.  Ca2+ content in each
ample was then normalized to the respective protein con-
entration measured with the Bio-Rad DC protein assay
able 1
alf-maximal inhibitory concentrations of osteogenic differentiation (ID50) and ce
ouse and marmoset ESCs.
Compound ID50 (differentiation inhibition, Ca2+) [g/ml] 
Mouse Marmose
LiCl n/a 0.4 ± 0.03
NaCl  n/a 790 ± 256
LiAc  48 ± 11.3 n/a 
NaAc 100 ± 21 52 ± 9.6 
AlCl3 0.7 ± 0.02 80 ± 23.8
AlOH3 0.0055 ± 0.0035 0.0014 ± orts 2 (2015) 165–174 167
reagent as described [23]. Calcium content was  normalized
to solvent only controls and concentration-response curves
charted. The half-maximal inhibitory dose (ID50) for each
compound was  taken from linear interpolation of the curve.
2.7. Statistical analysis
Data significance was decided using a web-based one-
way ANOVA and Tukey HSD post hoc test (http://faculty.
vassar.edu/lowry/anova1u.html) or unpaired Student’s t-
test as appropriate. All results are represented as average
of five independent replicates ± standard deviation.
3. Results
3.1. Osteogenic differentiation potential of marmoset
ESCs
ESCs from the marmoset, Callithrix jacchus, a New World
monkey, have been previously derived [18,24,25] and been
shown to be capable of producing osteoblasts that cal-
cify their extracellular matrix [16]. Calcified extracellular
matrices had been previously described as dark colored
light-dense areas [26]. Those dark areas were observed in
cultures from both mouse and marmoset ESCs via bright
field microscopy on day 30 of osteogenic differentiation
(Fig. 1A). Alizarin Red S staining of cultures confirmed the
presence of calcified extracellular matrix in such dark areas.
The overall amount of calcification between the marmoset
and the mouse cells was  comparable (Fig. 1B).
3.2. Differential sensitivity of mouse and marmoset ESCs
to lithium derivatives and controls
Previous literature has suggested that lithium chloride,
actively used in psychiatric pharmaceuticals, possesses
the capacity for inducing skeletal teratogenicity [27]. In
addition, our own  research has suggested that lithium
derivatives cause skeletal teratogenicity in certain con-
centration ranges [22]. To test the predictive aptitude of
a non-human primate based EST for lithium derivatives,
mouse and marmoset osteogenic ESC cultures were treated
with lithium and aluminum compounds. Sodium chloride
and lithium acetate served as a control for chloride in
lithium chloride to ensure that observed effects were due to
lithium activity. Sodium acetate was included as a control
for acetate in lithium acetate.
Lithium chloride treatment of mouse ESC osteogenic
cultures did not result in the establishment of an ID50 value
ll viability (IC50) for chloride and aluminum compounds determined with
IC50 (cytotoxicity, MTT) [g/ml]
t Mouse Marmoset
 n/a 24.6 ± 14.8
 n/a n/a
n/a n/a
n/a n/a
 809 ± 137 204 ± 144
0.0013 n/a n/a
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) Bright
ith ArseFig. 1. Osteogenic differentiation ability in mouse and marmoset ESCs. (A
(B)  Quantification of calcium deposit in osteogenic cultures determined w
with a Student’s t-test.
(Fig. 2). Instead, calcification was dose-dependently up-
regulated over control values in the absence of a cytotoxic
effect. In contrast to mouse ESC cultures, LiCl induced a
sharp drop in mitochondrial dehydrogenase activity, which
is a routinely used and widely accepted test for cyto-
toxicity [3,28,29], in marmoset ESCs at a concentration
of 100 g/ml. LiCl-treated osteogenic marmoset ESC cul-
tures also demonstrated a dose-dependent decrease in
calcification as concentration increased with an ID50 at
0.4 ± 0.03 g/ml, almost two orders of magnitude lower
Fig. 2. Cytotoxicity and bone mineral matrix assessment in mouse and marmo
Morphology of cultures. (B) Reduction in survival rate and calcium content is giv
is  represented as means of six technical replicates of n = 3 ± SD. *p < 0.05, One-Wafield images and Alizarin Red S staining identifying mineralized calcium.
nazo III, n = 3, five technical replicates each ± SD. p-value was established
than the IC50. These results classify lithium chloride as tera-
togenic in marmoset, but not in mouse.
Comparatively, murine osteogenic cultures treated with
sodium chloride featured consistently elevated calcifica-
tion levels with a 3-fold increase observed in the lowest
tested concentration (Fig. 2B). No reduction in calcification
was  observed in any tested concentration. Sodium chloride
treated marmoset ESCs, in turn, displayed a half-maximal
inhibitory dose at 790 ± 256 g/ml. Sodium chloride-
treated murine and marmoset osteogenic cultures followed
set osteogenic cultures treated with lithium and sodium chloride. (A)
en as percentage of non-compound treated cultures (solvent only). Data
y ANOVA significantly below untreated solvent control.
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Fig. 3. Cytotoxicity and bone mineral matrix assessment in mouse and marmoset osteogenic cultures treated with lithium and sodium acetate. (A) Pho-
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oomicrographs of cultures treated with concentrations of compounds as i
unction of percent solvent control. Data is represented as means of three
ne-way ANOVA significantly lower than untreated vehicle control.
elatively similar patterns of dose-dependent decreases
n cell viability. In both cases, half maximal viability was
pproached, but not achieved within the test concentration
ange. The absent cytotoxicity coupled with a relatively
igh ID50 concentration qualified sodium chloride as non-
ytotoxic and non-embryotoxic in neither species.
Lithium acetate treatments resulted in a significant
eduction in calcification at the highest tested concentra-
ion, while calcification levels remained above the 50%
ark in marmoset ESCs for all concentrations tested
Fig. 3A and B). No decrease in cellular viability was
oted upon exposure with this compound. In contrast,
odium acetate treatment induced a reduction in calcifica-
ion at concentrations where viability was still around 100%
Fig. 3B). Although this effect was noted in both species,
armoset ESCs were more sensitive to sodium acetate than
ouse ESCs.
.3. Common sensitivity of mouse and marmoset ESCs to
luminum and controls
In order to further assess response variation between
ouse and marmoset ESC osteogenic cultures, effects on
alcification levels were also investigated in aluminum
hloride, another compound actively used in certain classes
f pharmaceuticals with known detrimental effects on the. (B) Cell viability and calcium deposit in treated cultures is graphed as a
dent experiments, each including six technical replicates ± SD. *p < 0.05,
developing skeleton [30–32]. Cells were treated with alu-
minum hydroxide as a control for the chloride in aluminum
chloride. In aluminum chloride- and aluminum hydroxide-
treated mouse ESC cultures, a dose-dependent decrease in
calcification was observed with increasing concentration
of the test compound (Fig. 4). A slightly steeper decrease in
calcification was  observed in aluminum hydroxide-treated
cells. The similar response pattern between the alu-
minum chloride and hydroxide compounds infers that the
observed teratogenic effect may  be due to the presence of
aluminum at those test concentrations. Comparable dose-
dependent decreases in calcification were observed in
marmoset ESC osteogenic cultures treated with aluminum
chloride or hydroxide. However, calcification reduction in
aluminum chloride-treated cultures was  not as dramatic
compared to osteogenic murine responses.
The similarity between mouse and marmoset ESC
responses to treatment with aluminum compounds as
summarized in Table 1, suggests the potential for response
overlap between species utilized for in vitro teratogenicity
assessments. However, whether or not this overlap occurs
may  depend on the chemical in question. Lithium is chem-
ically similar to aluminum and yet did not produce similar
responses between mouse and marmoset ESC cultures
following treatment with lithium compounds (Table 1).
Therefore, observed variations in response may  be due to
variability in species sensitivity to particular compounds.
170 L. Walker et al. / Toxicology Reports 2 (2015) 165–174
ouse an
 charted
l, one-wFig. 4. Cytotoxicity and differentiation inhibition in aluminum treated m
entiation. (B) Values measured for cell viability and calcium deposit were
technical replicates of n = 3 ± SD. *p < 0.05 below untreated vehicle contro
3.4. Differential sensitivity to skeletal teratogens in ESCs
from Old and New World monkeys
Because of their close phylogenetic relationship with
humans, primates share a large number of traits important
in human reproduction. However, the reproductive biol-
ogy of many small primates including Callithrix, is distinct
from that of humans and Old World monkeys [33]. Because
of the closer relationship between humans and Old World
monkeys, we next investigated whether ESCs from the rhe-
sus monkey, Macaca mulatta, showed similar responses to
compounds as the marmoset ESCs. Rhesus ESCs are gen-
erally capable of responding to osteogenic triggers with
enhanced matrix mineralization [17].
In order to compare the responsiveness of mouse, mar-
moset and rhesus ESCs to embryotoxic compounds, the
embryotoxic potential of 5-fluorouracil (5-FU) and all-
trans retinoic acid (atRA) in each species were compared
against murine ESCs using the skeletal EST protocol [59].
Both compounds were previously shown to act as strong
skeletal teratogens in the mouse, both in vivo and in the
EST [3,6,14,34–38]. Penicillin G (PenG) was included as a
non-embryotoxic compound [21]. Effects on differentia-
tion were assessed via calcium deposition quantification
assay while cell viability was again measured with the MTT
assay.
In 5-FU-treated cells, similar decreases in cell via-
bility were observed in mouse, marmoset and rhesusd marmoset osteogenic ESC cultures. (A) Morphology on day 14 of differ-
 in percent of the untreated control. Data is represented as means of six
ay ANOVA.
ESC osteogenic cultures (Fig. 5A). However, the mouse
ESCs were the most sensitive to the cytotoxic effects
of this compound, while marmoset and rhesus ESCs
were equally sensitive. Measured calcification patterns
in mouse, marmoset and rhesus ESC osteogenic cultures
all followed dose-dependent decreases in mineraliza-
tion with increased 5-FU concentration. Compared to
the mouse, the marmoset cells were more sensitive,
but the rhesus cells were less sensitive (Fig. 5B and C).
However, in both primate cells, the ID50 was approx-
imately two orders of magnitude lower that the IC50,
indicating a strong teratogenic effect in both primate cell
types.
Exposure to atRA treatment again caused cytotoxicity
at lower concentrations in mouse ESC cultures than in
both primate cell cultures. However, both mouse and rhe-
sus ESC osteogenic cultures displayed a 2–2.5-fold increase
in calcification at lower atRA concentrations, followed by
a dose-dependent decrease in mineralization as concen-
tration of atRA increased (Fig. 5A). Calcification levels in
atRA-treated marmoset ESC osteogenic cultures resem-
bled those of the untreated control at lower concentrations
before gradually decreasing dose-dependently. Mouse ESC
osteogenic cultures demonstrated the highest sensitivity
as calcification at the highest tested concentration in the
mouse ESC cultures was  significantly lower than mineral-
ization levels observed in marmoset and rhesus cultures at
those same concentrations (Fig. 5B and C).
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Fig. 5. Comparison of marmoset and rhesus ESCs for their sensitivity to skeletal embryotoxicants. (A) Juxtaposition of cell viability and mineralization
m  culture
c 50 value
c  by comp
r
i
f
(
a
teasurements taken from osteogenic mouse, marmoset and rhesus ESC
ontrol,  one-way ANOVA. (B) Table contrasting the resulting IC50 and ID
oncentration difference between IC50 and ID50 for each species grouped
ight  cross the IC50 value.
According to its role as a non-embryotoxic agent, PenG
nduced cytotoxicity only at high test concentrations, but
ailed to cause inhibition of calcification in all species
Fig. 5A–C). Results of this assay correctly identified 5-FU
nd atRA as strongly teratogenic compounds across the
hree species and PenG as non-teratogenic.s treated with atRA, 5-FU and PenG. *p < 0.05 below untreated vehicle
s taken from the concentration-response curves. (C) Chart depicting the
ound. The left cross on each line indicates the respective ID50 value, the
Observed differences in primate cell viability and calcifi-
cation at higher concentrations of 5-FU and atRA compared
to the mouse ESC osteogenic cultures suggest that both
marmoset and rhesus ESCs may  be less sensitive than
mouse ESCs to particular classes of cytotoxic compounds,
while they are more sensitive toward embryotoxic effects
logy Rep172 L. Walker et al. / Toxico
of others, again underlining our results obtained with the
lithium and aluminum derivatives. Thus, murine-based
cytotoxicity and in vitro skeletal embryotoxicity assays may
provide limited predictivity for extrapolation of results to
other species. Though these results indicate that both mar-
moset and rhesus ESC osteogenic cultures are capable of
assessing cytotoxicity and embryotoxicity, the lack of a
defined pattern of variability between primate osteogenic
cultures indicates that response of non-human primate
ESCs may  also vary between different compound classifi-
cations.
4. Discussion
Since its introduction and subsequent validation, the
classic EST has been updated to include additional tissue
and molecular endpoints. Such revisions have proven to
be extremely useful in allowing for reductions in assay
duration as well as providing embryotoxicity responses
across tissue types. Skeletal toxicity evaluations in par-
ticular stand much to gain from recent improvements
as musculoskeletal birth defects account for 5% of all
infant deaths. Previous work has demonstrated the capac-
ity of the EST to identify inhibitory effects of toxicants on
skeletal development based on the relationship between
compound cytotoxicity as measured by reduction in mito-
chondrial dehydrogenase activity and inhibition of normal
differentiation [6,10].
In developmental toxicology, cytotoxicity of a chemical
is often established with MTT  assays and previous ver-
sions of stem cell based developmental toxicity assays also
rely on this read-out measure [4,39,40]. However, strictly
speaking the MTT  assay is a measure for the mitochondrial
activity of cells and is therefore only an indirect indicator
of cytotoxicity. This could be of concern as mitochondrial
activity in stem cells is different than in somatic cells. For
instance, stem cells have a low number of mitochondria
[41], which increases as cells differentiate concurrently
with an increase in mitochondrial DNA content [42]. Future
studies will need to compare different endpoints of cyto-
toxicity, such as apoptosis or proliferative capacity, for their
predictivity in vitro, which is beginning to be done for other
tissue endpoints [43].
One of the main drawbacks of the murine based EST
is that it provides a narrow mechanistic understanding of
human development and response to toxicants. Yet, poten-
tial human sources of cells are either ethically unaccepted
in some countries or have been suggested to be of flawed
quality. For example, human induced pluripotent stem
cells (hiPSCs) often exhibit varying differentiation poten-
tial, due to altered global methylation or transcript number
of master regulators, which greatly affects their quality and
usability [44–46] and seems dependent on the choice of
reprogramming factors [47]. As such, a proposed solution
has been to update the EST to feature non-human primate
ESCs as a basis for embryotoxicity assessment. Here, we
applied a marmoset ESC-based EST in order to evaluate the
efficacy of non-human primate ESCs in predicting potential
negative side effects on the developing skeletal system. Our
proof-of-concept results show that non-human primateorts 2 (2015) 165–174
ESCs and murine ESCs respond differently in embryotox-
icity screens.
Our preliminary comparison screen of murine and
non-human primate ESC-based EST assessments indi-
cated that non-human primate ESCs were more tolerant
toward the toxic effects of 5-FU and atRA compared to
murine ESCs. Thus, it is possible that EST embryotoxic-
ity results could be affected by species-driven response
variation. Such variations may be attributed to differ-
ences in mouse and non-human primate molecular and
genomic response to test compounds. Similar species-
based discrepancies attributed to variations in molecular
and genomic response have been observed in other studies
[48]. Discrepancies between the effects of trauma, burns,
and exposure to endotoxemia on temporal gene response
patterns and inflammation signaling pathways were noted
between mouse models and human patients. Though
responses were similar among human subjects, compari-
son of mouse and human results showed poor correlation
of responses between the two  groups at the molecular and
genomic levels. As all compounds function at the molec-
ular and/or genomic level, these results call into question
the extrapolation efficacy of mouse responses as predic-
tors of response in humans [49,50]. Given the evolutionary
closeness between humans and non-human primates [51],
it is probable that a mechanism of variation similar to that
seen in the Seok et al. [48] study is operating in this study
between the murine ESC and marmoset ESC cultures.
Aluminum chloride assay results in murine and mar-
moset ESCs both demonstrated dose-dependent decreases
in calcification. As decreases were observed in both
AlCl3- and AlOH3-treated cultures, it is probable that Al3+
is responsible for the osteotoxic effects of AlCl3 expo-
sure. Recent studies on aluminum osteotoxicity in infants
have reported a strong connection between pre- and
perinatal aluminum overexposure and metabolic bone dis-
eases as well as potential long term consequences on
bone health and development following exposure to alu-
minum compounds during critical periods of development
[30]. At the molecular level, aluminum has been sug-
gested to antagonize bone formation through activation
of the oxidative-stress-mediated c-Jun N-terminal kinase
signaling pathway and subsequent induction of apoptosis
in osteoblasts [52].
Overall evaluation of cell viability and calcification assay
results indicated that lithium chloride and its derivatives
possess skeletal teratogenic capacity, though the potency
of teratogenic effects may  vary depending on the other
members of the lithium compound complex. Treatment
of marmoset ESC osteogenic cultures with both lithium
chloride and lithium acetate compounds demonstrated
noteworthy, but species-specific decreases in calcification,
which were absent in sodium chloride. In contrast, sodium
acetate was teratogenic in both species. These results
suggest lithium to not be the chief skeletal teratogenic com-
ponent, but rather the combination with the complexed
chemical that results in the detrimental outcome on dif-
ferentiating osteoblasts. Additionally, varied response to
lithium and sodium compound treatment between murine
and marmoset ESC cultures suggests that species varia-
tion in embryotoxic assessments may  yield a varied and
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otentially narrow scope of responses to the compounds
nder investigation.
Within the cell, lithium chloride has been suggested to
perate via inhibition of glycogen-synthase-kinase 3beta
GSK3) to intensify canonical Wnt  signaling, which ulti-
ately encourages upregulation of genes required for
steogenic differentiation. Previous studies have reported
ose-dependent bone defects incurred by disruption of the
anonical Wnt  signaling pathway with lithium chloride
nd support the dose dependent effects of lithium chloride
reatment on mouse ESC cultures reported here [53,54].
Conversely, marmoset ESCs were much more sensitive
o the detrimental effects of lithium chloride. Although this
ay  be largely due to increased cytotoxicity of lithium
hloride at higher concentrations, the differentiation effect
ccurred at concentrations that were two orders of mag-
itude lower than the cytotoxic effect. Considering that
ther studies have reported variations between mouse and
uman response at the molecular level, it is likely that a
imilar explanation stands for the observed differences in
ithium chloride response in this study. Lithium chloride is
ften included in embryotoxicity screens as a control com-
ound in the class of the moderate embryotoxicants [21].
ntriguingly, the classical EST has a low prediction value for
he moderate embryotoxicants [55] and it stands to reason
hat this low predictivity in this specific class of teratogens
tems at least partially from using a less predictive species
uch as the mouse instead of primate cells.
Of concern are our findings on the differential sensitivity
etween marmoset and rhesus ESCs that exist even in the
mall set of chemicals tested here. Although the three con-
rol chemicals that were tested exhibited predictive effects,
ith 5-FU and atRA being teratogenic and PenG not, the
ctual half-maximal inhibitory doses varied substantially.
t is thus evident that there may  be significant general dif-
erences in the responses of different non-human primate
ells to drugs and toxicants in a broader screen encompass-
ng more chemicals as is typically done with mouse cells
6,11]. However, our limited results already suggest that
his existing dose discrepancy may  make risk predictions
or human use and the definition of adverse outcome doses
ifficult. For the reasons laid out in this manuscript, human
mbryonic stem cells, which are already beginning to be
xplored for such purpose [56–58], may  provide the most
ccurate information regarding the teratogenic potential of
hemicals and future studies will need to show whether the
thically accepted human induced pluripotent stem cells
re also predictive in such assays.
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